( BERKELEY HEIGHTS N.J.--(BUSINESS WIRE)...)Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study,Results at the American Society of Clinical Oncology Annual Meeting,Health

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--May 24, 2007 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced today that it will report results from a Phase I pharmacologic trial of sapacitabine (CYC682), a novel orally-available nucleoside analog, in patients with advanced leukemias or myelodysplastic syndromes (MDS), at the American Society of Clinical Oncology's (ASCO) Annual Meeting at McCormick Place in Chicago. Details of the presentation are as follows:

Abstract # 7063, Poster # M8

Phase I study of sapacitabine, an oral nucleoside analogue, in patients with advanced leukemias or myelodysplastic syndromes.

General Poster Session: Saturday, June 2, 2007, 8:00 AM - 12:00 pm Central Time

Presenters: Dr. Hagop Kantarjian, Professor of Medicine and Chairman, Department of Leukemia and Dr. William Plunkett, Professor and Chief, Section of Molecular and Cellular Oncology, Department of Experimental Therapeutics both at the University of Texas M.D. Anderson Cancer Center (UTMDACC) in Houston, Texas.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Two Cyclacel drugs are in Phase II trials: sapacitabine (CYC682), an orally-available, cell cycle modulating nucleoside analog, for the treatment of cutaneous T-cell lymphoma (CTCL) and seliciclib (CYC202), an orally-available CDK (cyclin dependent kinase) inhibitor, for the treatment of lung cancer. Sapacitabine is also in Phase I trials in patients with hematologic malignancies. CYC116, an orally-available, Aurora kinase and VEGFR2 inhibitor, is at the IND stage. Several additional programs are at an earlier stage.

Please visit http://www.cyclacel.com/cyc/investors/news/pressreleases for additional information.

Note: The Cyclacel
'"/>

Page: 1 2 3
Related medicine technology :

1. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
2. Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine and Seliciclib at AACR
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)